However, normal expression of VSIG-3 is restricted to brain and testis tissues, and though VSIG-3 upregulation has been observed in gastric and hepatocellular carcinomas, its expression has not been reported in normal immune cells, limiting the relevance of this VISTA binding partner in other settings or cancers. Here, IGSF11 is linked to hepatocellular carcinoma.